Abstract. The pharmacological profile of (S)7(2{2[(E)2cyclopentylvinyl]5methyloxazol 4yl}ethoxy)2[(2E,4E)hexadienoyl]1,2,3,4tetrahydroisoquinoline3carboxylic acid (KY201), a peroxisome proliferatoractivated receptor (PPAR) g agonist, was compared with that of rosiglitazone in ovariectomized rats. The serum triglyceride and nonesterified fatty acid reducing effects of KY201 at 3 and 10 mg/kg per day for 6 weeks were similar to those of rosiglitazone despite its weaker PPARg agonistic activity. KY201 had no effects on body weight gain, blood volume, or heart and adipose weights, while rosiglitazone at 10 mg/kg per day increased them. KY201 had few effects on bone mineral density (BMD) or fat in marrow (FM), whereas rosiglitazone strongly decreased BMD and increased FM. The PPARγ agonistic activity of KY201 was weaker than that of rosiglitazone in ST2 cells, and KY201 reduced osteoblast differentiation and increased adipocyte differentiation less potently than rosiglitazone in rat bone marrowderived mesenchymal stem cells. KY201, but not rosiglitazone inhibited protein tyrosine phosphatase 1B (PTP1B) and increased phosphorylation of the insulin receptor in HepG2 cells. These results suggest that the hypolipidemic effects of KY201 are similar to those of rosiglitazone, but with less adverse effects, due to the combination of PPARg partial activation and PTP1B inhibition. KY201 would be useful for treatments of diabetic patients at high risk of osteoporosis, cardiovascular disease, and/or obesity.
Introduction
The number of patients with type 2 diabetes has been increasing worldwide over the past few decades, and is now a serious global health burden. Type 2 diabetes causes hyperglycemia due to impaired insulin secretion and/or insulin resistance, resulting in glucotoxicity in various organs, which leads to severe complications including cardiovascular diseases, nephropathy, retino pathy, and peripheral neuropathy (1) . Thus, patients with type 2 diabetes have been treated with insulin or insulin secretagogues such as sulfonylureas, glinides, dipeptidyl peptidase IV (DPPIV) inhibitors, and glucagonlike peptide1 (GLP1) analogues or insulin sensitizers such as metformin and glitazones to normalize hyperglycemia (2, 3) . Although sulfonylureas and glinides effectively lower plasma glucose by stimulating insulin release from pancreatic beta cells, they may cause critical hypoglycemia (2) . DPPIV inhibitors and GLP1 ana logues stimulate insulin release in a glucosedependent manner; therefore, they have been used as safer insulin secretagogues (3, 4) . Insulin sensitizers are effective in reducing plasma glucose without an increase in plasma insulin levels in type 2 diabetic patients with insulin resistance and hyperinsulinemia. However, only metformin and two glitazones are clinically used as insulin sensitizers. Metformin has been used for a long time, but has moderate efficacy and may cause lactic acidosis (5, 6) . Although glitazones such as rosiglitazone and pioglitazone, peroxisome proliferatoractivated receptor (PPAR) g agonists, have been used as effective insulin sensitizers, they have adverse effects such as fluid retention, hemodilution, body weight gain, hepato toxicity, the risk of heart failure, and reductions in bone mineral density (BMD) (7, 8) . Thus, a large number of PPARg or PPARa/g agonists have been synthesized to find a safer and more efficacious insulin sensitizer; however, none have been successfully developed to date (9) .
The novel PPARa/g agonist (S)7(2{2[(E)2 cyclopentylvinyl]5methyloxazol4yl}ethoxy) 2[(2E,4E)hexadienoyl]1,2,3,4tetrahydroisoquinoline 3carboxylic acid (KY201, Fig. 1 ) was reported to exhibit protein tyrosine phosphatase1B (PTP1B) inhibi tory activity (10) . PTP1B is known as a nonreceptor type tyrosine phosphatase and negatively regulates insu lin and leptin signaling (11, 12) . The genetic deletion or pharmacological intervention of PTP1B is known to have antidiabetic and antiobesity effects by amplifying insulin and leptin signaling, respectively (13, 14) . KY 201 was previously reported to reduce plasma glucose and triglyceride (TG) levels more effectively than rosi glitazone in KKA y mice, even though both compounds have similar human PPARg agonistic activities in COS1 cells (10) , which suggests the involvement of PTP1B inhibition in its insulinsensitizing effects. PPARgrelated adverse effects such as fluid retention and hepatomegaly were weaker with KY201 than with rosiglitazone in normoglycemic mice (10) . However, its safety for cardiac hypertrophy, obesity, and reductions in BMD, all PPARgrelated adverse effects, remains to be determined.
In the present study, the hypolipidemic effects and adverse effects of KY201, including fluid retention, cardiac hypertrophy, obesity, and reductions in BMD, were compared with those of rosiglitazone, a PPARg full agonist, in ovariectomized (OVX) female rats, which are used widely as an experimental osteoporosis model with normoglycemia, insulin resistance, mild obesity, and hyperlipidemia (15) .
Materials and Methods

Materials and animals
KY201, rosiglitazone, and ertiprotafib were synthe sized in our laboratories. ST2 cells and HepG2 cells were purchased from Rikagaku Kenkyusho (Tsukuba) and Dainippon Sumitomo Pharma Co., Ltd. (Osaka), respectively. Roswell Park Memorial Institute (RPMI) 1640 medium and Dulbecco's modified Eagle's medium (DMEM, Nissui Pharmaceutical, Co., Ltd., Tokyo) or alpha Modified Eagle Minimum Essential Medium (aMEM; Life Technologies, Inc., Carlsbad, CA, USA) that contained 10% fetal bovine serum (JRH Bioscience, Inc., Lenexa, KS, USA), 0.3% NaHCO 3 , and 1% penicillinstreptomycin were used for the cell culture. The antiphosphorylated insulin receptor, antiinsulin receptor, and peroxidaseconjugated antibody were purchased from Merck Millipore (Billerica, MA, USA), Sntacruz (Dallas, TX, USA.) and Cell Signaling Technology, Inc. (Danvers, MA, USA), respectively. Female F344/NSlc rats were purchased from Japan SLC, Inc. (Hamamatsu) and individually housed under conditions with controlled temperature, humidity, and light exposure (12 h light-dark cycle) and were allowed ad libitum access to commercial standard rodent chow (CE2; CLEA Japan, Inc., Tokyo) and tap water. Animals were handled in accordance with the "Guidelines for Animal Experimentation" approved by The Japanese Pharmacological Society, and all procedures were approved by the Animal Ethical Committee of Kyoto Pharmaceutical Industries. KY201, rosiglitazone, and ertiprotafib were dissolved in dimethyl sulfoxide (DMSO; Nacalai Tesque, Kyoto); each drug solution was diluted in buffer or medium for in vitro study or suspended in 0.5% methylcellulose (Nacalai Tesque) for oral administration to animals.
OVX rats and treatment
Eightweekold female F344/NSlc rats were anesthe tized using ketamine (37.5 mg/kg, i.p.) and xylazine (7.5 mg/kg, i.p.), and bilateral ovariectomy was per formed. Two days after surgery, OVX rats were random ized into 5 groups: vehicletreated group and KY201 and rosiglitazonetreated groups at 3 and 10 mg/kg per day. A shamoperated group and satellite group for a pharmacokinetic study were also used. Rats were orally administered vehicle or drugs for 6 weeks and then deeply anaesthetized with pentobarbital sodium (50 mg/kg, i.p.). Blood was collected from abdominal aorta and total blood volumes were measured. Serum glucose, TG, and nonesterified fatty acid (NEFA) levels were measured colorimetrically using commercial kits (Wako Pure Chemical, Ind., Ltd.). Abdominal and subcutaneous adipose tissues, and hearts were isolated and weighed. Lumbar vertebra (L2 -L4) and bilateral femurs were fixed with 70% ethanol and stored at 4°C until the measurement of BMD. Lumbar vertebra and femurs were scanned by Xray computed tomography (LaTheta; Aloka Co., Ltd., Tokyo) and reconstruct images were analyzed. After computed tomography analyses, the femurs were embedded in paraffin and 5mm sections were cut on a rotary microtome. Sections were stained with hematoxylin and eosin. The relative area of fat in the marrow cavity was determined by microscopy (BZ8100; Keyence Corporation, Osaka).
Plasma concentrations of KY-201 and rosiglitazone
Satellite groups of OVX rats were orally administered KY201 and rosiglitazone at 3 and 10 mg/kg per day for 6 weeks. On day 42, blood samples were taken from the jugular vein at 0.25, 0.5, 1, 3, 5, 8, and 24 h after the drugs had been administered. Plasma concentrations of KY201 and rosiglitazone were determined using a high performance liquid chromatography system consisting of a pump (PU980; JASCO, Tokyo), UV detector (UV970, JASCO), autoinjector (AS950, JASCO), and CosmosilMSII column (5 mm, 4.6 mm × 150 mm; Nacalai Tesque). The time to reach plasma maximal concentrations was between 0.5 and 1 h after the admin istration of KY201 and rosiglitazone at doses of 3 and 10 mg/kg per day.
PPARg agonist activity
ST2 cells were cultured in RPMI1640 under 5% CO 2 at 37°C. The fulllength mouse PPARg 1 plasmid (Open Biosystems, Inc, Huntsville, AL, USA) and human RXRa plasmid (GeneCopoeia, Inc., Rockville, MD, USA) with the reporter plasmid pGL3PPREx4 tkluc were electroporated into ST2 cells using Nucleofector II (AAD1001S; Lonza, Basel, Switzerland). Cells were then seeded in 96well plates at a density of 1.5 × 10 3 cells/well and incubated for 24 h in the presence or absence of the test compound. Luciferase activities were determined using a commercial kit (PicaGene LT7.5; TOYO BNet CO., Ltd., Tokyo). Each maximal activity was taken as 100% and median effective concentration (EC 50 ) values were calculated.
Isolation of rat bone marrow-derived mesenchymal stem cells (BMSCs)
Bone marrowderived mesenchymal stem cells were isolated from eightweekold female F344/NSlc rats. Animals were deeply anesthetized with pentobarbital sodium (50 mg/kg, i.p.) and bled to death. The femoral bones were isolated and placed in fresh phosphate buffered saline (PBS, pH 7.4) containing 1% penicillinstreptomycin. The bones were then cut at the ends and flushed with aMEM. After centrifugation, the pre cipitated cells were resuspended in aMEM and plated in 10cm dishes at 5% CO 2 and 37°C. Adherent cells were then cultured for 1 week and used as BMSCs.
In vitro osteoblast differentiation in rat BMSCs
BMSCs were seeded in 96well plates at a density of 4 × 10 3 cells/well. Test compounds were added 24 h later and cultured for 4 days. Cells were then washed with PBS (pH 7.4) and lysed in 50 mL saline containing 1% NP40. The reaction was started by the addition of 50 mL of 10 mM pnitrophenol phosphate in 50 mM ethanol amine and stopped by the addition of 50 mL of 1 N NaOH after 30 min incubation at 37°C. Alkaline phosphatase (ALP) activities were determined by measuring the absorbance at 405 nm.
In vitro adipocyte differentiation
BMSCs were seeded in 96well plates at a density of 4 × 10 3 cells/well. Test compounds were added 24 h later and cultured for 4 days. Glycerol3phosphate dehydrogenase (GPDH) activities were measured using a commercial GPDH assay kit (Primary Cell Co., Ltd., Sapporo). BMSCs were seeded separately in 6well plates at a density of 8 × 10 4 cells/well, and cultured for 4 days. Total RNA was prepared using Trizol (Life Technologies, Inc.) according to the manufacturer's instructions. PPARg2, CCAAT/enhancerbinding protein alpha (C/EBPa), GPDH, lipoprotein lipase, adipocyte protein 2, and adiponectin mRNAs were determined by realtime polymerase chain reaction (realtime PCR).
Real-time PCR
To synthesize cDNAs, 0.1 mg total RNAs were reverse transcribed using a commercial kit (Cosmo Bio Co., Ltd., Tokyo). The reaction was performed under the following conditions: synthesis at 37°C for 15 min and heat inactivation of reverse transcriptase at 85°C for 1 min. cDNAs were then stored at −30°C until use. Real-time PCRs were performed in 10 mL of the total reaction volume containing 5 mL of cDNAs, individual primer pairs, a fluorescentlylabeled probe, and the commercial reagent (Light Cycler 480 Probes Master; Roche Diagnostics, Tokyo) according to the manufacturer's protocol using Light Cycler 480 (Roche Diagnostics). Reactions were initiated by incubating at 95°C for 10 min and PCR (denaturation at 95°C for 10 s and annealing and extension at 60°C for 30 s) was performed for 45 cycles. The expression of each mRNA was standardized with 18S RNA. The sequences of primers were designed using the Universal ProbeLibrary (Roche Diagnostics): PPARg2, 5′-GAAAGAAGCTGT GAACCACTAA-3′ and 5′-GAATGGCATCTCTGT GTCAA-3′; C/EBPa, 5′-ATAAAGCCAAACAGCGCA AC-3′ and 5′-CGGTCATTGTCACTGGTCAA-3′; GPDH, 5′-AGGGCCTCGTGGACAAGT-3′ and 5′-CAGGCA GCAGATGAACTCAC-3′; lipoprotein lipase, 5′-CAG AGAAGGGGCTTGGAGA-3′ and 5′-TTCATTCAG CAGGGAGTCAA-3′; adipocyte protein 2, 5′-GAG GAGACGAGATGGTGACAA-3′ and 5′-GCTCATGCC CTTTCGTAAAC-3′; adiponectin, 5′-TGGTCACAA TGGGATACCG-3′ and 5′-CCCTTAGGACCAAGA ACACCT-3′; 18S rRNA, 5′-GGTGCATGGCCGTTC TTA-3′ and 5′-TCGTTCGTTATCGGAATTAACC-3′.
PTP1B inhibitory activity
PTP1B inhibitory activities were determined in the absence or presence of the test compounds in 100 mL of 100 mM 4(2hydroxyethyl)1piperazineethanesulfonic acid (HEPES) buffer (pH 7.2) containing a human PTP1B enzyme (Enzo Life Sciences, Inc., Farmingdale, NY, USA), 3 mM pnitrophenol phosphate, 1 mM dithiothreitol, 1 mM ethylenediaminetetraacetic acid (EDTA), and 0.001% TritonX. The reaction was started by the addition of pnitrophenol phosphate and stopped by the addition of 50 mL of 1N NaOH after 10 min incubation at 37°C, and absorbance was determined at 405 nm. The DMSOtreated enzymatic activity level was taken as 100%, and 50% inhibitory concentration (IC 50 ) was calculated.
Insulin receptor phosphorylation in HepG2 cells
HepG2 cells suspended in DMEM were seeded in 6well plates at a density of 1 × 10 6 cells/well and cultured under 5% CO 2 at 37°C for 24 h and then for 6 h in serumfree DMEM. Cells were cultured in the presence or absence of test compounds for 1 h, followed by incubation with 1 nM insulin for 10 min. Cells were washed with 20 mM TrisHCl buffer (pH 7.5) containing 5 mM EDTA2Na, 10 mM sodium fluoride, 10 mM sodium bglycerophosphate, 10 mM Na 4 P 2 O 7 , and 10 mM NaVO 4 ; harvested; and suspended in 20 mM TrisHCl buffer (pH 7.5) with 1 mg/mL pamidinophenyl methanesulfonyl fluoride, leupeptin, 1 mg/mL antipain, 1 mg/mL benzamidine, and 1% Triton X100. The suspensions were added at a volume of 4:1 to 50 mM tris(hydroxymethyl)aminomethane (Tris)HCl buffer (pH 6.8) containing 10% sodium dodecylsulfate, 0.05% bromophenol blue, 50% glycerol, and 25% mercapto ethanol followed by heating and mixing at 100°C for 10 min. Each 30 mg aliquot of protein was loaded on a 7.5% polyacrylamide gel for electrophoresis at a con stant current of 30 mA/plate for 1 h, followed by blotting to a polyvinylidene difluoride (PVDF) membrane pre viously treated with 100% methanol. After blocking by 10% skim milk dissolved in 20 mM TrisHCl buffer (pH 7.5) containing 0.05% Tween 20 and 137 mM NaCl (TBST) for 1 h, the membrane was incubated with the antiphosphorylated insulin receptor antibody or anti insulin receptor monoclonal antibody diluted in TBST containing 1% skim milk (1:1000) followed by incuba tion with a peroxidaseconjugated antibody (1:1000). The protein content was determined using a chemilumi nescence reagent (ChemiLumi One Super; Nacalai Tesque) and Chem Doc and Image Lab software (BioRad Laboratories, Inc., Hercules, CA, USA).
Statistical analyses
All data are expressed as the mean ± S.E.M. The significance of differences was assessed by a twotailed studentʼs ttest for paired data for in vitro assays and by Dunnett's multiple comparison test for in vivo assays.
Results
Effects of KY-201 and rosiglitazone in OVX rats
The insulin sensitizing effects of KY201 were pre viously shown to be 10 times stronger than those of rosiglitazone in KKA y mice, despite its lower PPARg activity and plasma concentration. In this study, hypo lipidemic effects and adverse effects were investigated in OVX rats. Ovariectomy increased body weight gain, serum TG, and serum NEFA levels by 53%, 21%, and 22%, respectively, but had negligible effects on serum glucose levels. Rosiglitazone, but not KY201 increased body weight gain at 10 mg/kg per day. KY201 and rosiglitazone at 3 and 10 mg/kg per day reduced serum TG and NEFA levels to a similar extent (Table 1) . Ovariectomy increased adipose tissue weight by 19%, but had negligible effects on heart weight and blood volume (Fig. 2) . Rosiglitazone at 10 mg/kg per day significantly increased adipose tissue weight, heart weight, and blood volume, whereas KY201 at both doses did not. The plasma maximal concentrations of KY201 and rosiglitazone after their final administration were 0.54 and 6.17 mg/mL (1.1 and 12.5 mM, n = 2), respectively, at 3 mg/kg per day, and they were 3.56 and 17.99 mg/mL (10.0 and 50.3 mM, n = 2), respectively, at 10 mg/kg per day. Ovariectomy significantly decreased the BMDs of lumbar vertebra and femurs. Rosiglitazone significantly decreased the BMD of lumbar vertebra at 10 mg/kg per day, while KY201 did not (Fig. 3A) . KY201 at 10 mg/kg per day and rosiglitazone at both 3 and 10 mg/kg per day significantly decreased the BMD of the femur (Fig. 3B) . On hematoxylin and eosin staining analysis of sections, rosiglitazone more apparently increased fat in bone marrow cavity than KY201 in femurs (Fig. 4A) . Ovariectomy increased fat in the marrow cavity by 10%. Rosiglitazone further increased fat in the marrow cavity by 17% at 3 mg/kg per day and significantly increased it by 27% at 10 mg/kg per day, whereas KY201 had no effect (Fig. 4B) .
PPARg agonist activities
The transactivation of PPARg was investigated using a luciferase reporter assay. KY201 and rosiglitazone at 10 −7 -10 −5 M activated mouse PPARg in a concentra tiondependent manner. KY201 was 2 times weaker than rosiglitazone (EC 50 : 287 ± 88 and 148 ± 39 nM, respectively). The maximal activation level by KY201 was 54.1% ± 1.1% that of rosiglitazone (Fig. 5) .
Effects on osteoblast and adipocyte differentiation in BMSCs
In rat BMSCs, rosiglitazone significantly decreased ALP activities from 10 −9 M in a concentrationdependent manner, while KY201 significantly decreased it from 10 −7 M. The reducing effects of KY201 were signifi cantly weaker than those of rosiglitazone at 10 −8 -10 −5 M (Fig. 6A ). KY201 and rosiglitazone significantly increased GPDH activities from 10 −7 M in a concentra tiondependent manner, although the effects of KY201 The values are the mean ± S.E.M. (n = 8). *P < 0.05 and **P < 0.01 vs. the Control group. were significantly weaker than those of rosiglitazone at 10 −6 M and 10 −5 M (Fig. 6B) .
Effects on adiponenic gene expression in BMSCs
The effects of KY201 and rosiglitazone on adipocyte marker genes expression were examined in BMSCs. KY201 and rosiglitazone increased the expression levels of genes involved in adipocyte differentiation: PPARg, cEBPa, GPDH, lipoprotein lipase, adipocyte protein 2, and adiponectin, in a concentrationdependent manner. Although the effects of both drugs were similar at 10 −9 -10 −7 M, the effects of KY201 at higher than 10 −7 M were weaker than that of rosiglitazone; increases in expression levels by KY201 at 10 −6 and 10 −5 M were approximately 30% -80 % those of rosiglitazone (Fig. 7) .
Effects on PTP1B activity and insulin receptor phosphorylation
KY201 and ertiprotafib, a PTP1B inhibitor (16), inhibited PTP1B activity in a concentrationdependent manner, whereas rosiglitazone did not. The IC 50 values of KY201 and ertiprotafib were 3.7 ± 1.0 and 0.64 ± 0.24 mM, respectively (Fig. 8A) . The insulin sensitizing effect of KY201 was examined in a cellbased phos phorylation assay. KY201 significantly potentiated insulininduced insulin receptor phosphorylation from 2 × 10 −6 M in a concentrationdependent manner (Fig. 8B) .
Discussion
The present study was undertaken to determine whether KY201 showed hypolipidemic effects with less adverse effects than rosiglitazone in OVX rats, and, if any, to clarify their mechanisms. OVX rats are an experimental model for osteoporosis in postmenopausal woman, which shows a marked reduction in BMD, obesity, and hyperlipidemia, but not hyperglycemia (15, 17) . TG and NEFA, but not glucose levels were slightly increased by ovariectomy, and these increased TG and NEFA levels were similarly reduced by KY201 and rosiglitazone. Insulin is known to lower plasma TG and NEFA levels by inhibiting verylowdensity lipoprotein (VLDL) secretion from hepatocytes and uptake into adipocytes via lipoprotein lipase activation (18, 19) . PPARg agonists have been shown to reduce TG and NEFA levels by insulin sensitization in diabetic rats (20) . However, KY201 was found to exhibit partial human PPARg agonistic activity in COS1 cells (10), and its plasma concentrations in OVX rats were approxi mately 10 times lower than those of rosiglitazone. Thus, the effects of KY201 appear to be attributed, at least in part, to activity other than PPARg agonistic activity. KY201, but not rosiglitazone, inhibited PTP1B and increased insulinstimulated insulin receptor phosphory lation in HepG2 cells. PTP1B is known to negatively regulate the insulin signal by dephosphorylating the insulin receptor and insulin receptor substrate phosphory lated by insulin (11) . The overexpression of PTP1B in muscle has been proposed to cause insulin resistance (21) . Hepatic deletion and PTP1B inhibitors were shown to improve insulin resistance and reduce plasma glucose and TG levels in diabetic mice (14, 22) . The plasma concentrations of KY201 in OVX rats were compatible with PTP1B inhibitory concentrations. It is likely that KY201 showed hypolipidemic effects by partial PPARg activation and PTP1B inhibition, the effects of which were similar to those of rosiglitazone by full PPARg activation. Similar phenomena were observed in normoglycemic Zucker fatty rats with insulin resis tance. KY201 and rosiglitazone showed similar reduc ing effects on TG and NEFA levels and on elevated glucose levels in a glucose tolerance test (unpublished data). On the other hand, PTP1B inhibition was consid ered to more effectively exert insulinsensitizing effects in diabetic mice; the hypoglycemic and hypolipidemic effects of KY201 were approximately 10 times stronger than those of rosiglitazone, although its PPARg activa tion levels and plasma concentrations were lower (10) . However, the reason why the plasma maximal concentra tion of KY201 was lower than that of rosiglitazone is not clarified so far. Differences in molecular weights and/or acidic moieties could affect the plasma maximal concentrations.
Only a high dose of rosiglitazone significantly in creased body weight gain, adipose tissue weight, blood volume, and heart weight in OVX rats, which are all considered to be PPARgmediated adverse effects. PPARg agonists promote adipocyte differentiation from preadipocytes in abdominal and subcutaneous adipose tissue, resulting in adiposity (23) . PPARg agonistinduced fluid retention is attributed to the activation of epithelial Na + channel subunit gamma in the collecting duct and/or to Na + , K + ATPase activation via proximal tubular PPARg (24) . The cardiac hypertrophy caused by PPARg agonists appears to be induced by increased cardiac preload through fluid retention and/or cardio myotic PPARg activation (25, 26) . The increase in body weight gain may be due to adiposity and/or fluid retention. CT analyses demonstrated that ovariectomy reduced BMD in lumbar vertebra and femurs. BMDs in these regions were markedly lower due to the rosigli tazone treatment than the KY201 treatment. Insulin promotes osteoblastogenesis (27) and type 2 diabetic patients are at higher risk of bone fractures (8) . PPARg agonists are more likely to increase the risk of bone fractures in diabetic patients. Rosiglitazone and piogli tazone have been reported to increase the risk of bone fracture by decreasing BMDs in aged women (2, 8) , which is explained by a shift from osteoblast differentia tion to adipocyte differentiation by PPARg activation in BMSCs (28, 29) . Rosiglitazone, but not KY201 markedly increased fat in the bone marrow cavity in OVX rats.
KY201 has weaker adverse effects than rosiglitazone and this is considered to be due to its weaker PPARg agonistic activity. The PPARg agonistic activity of KY201, which was reported using human PPARg in COS1 cells (10) , was reexamined with a transactivation assay using murine PPARg in ST2 cells because trans activation activity varies depending on gene and cell types. The affinity and maximal activation levels of KY201 were 2 times lower than those of rosiglitazone. ST2 cells can differentiate into osteoblasts and adipo cytes (30, 31) , and PPARg agonists are known to promote adipocyte differentiation, resulting in a reduction in osteoblast differentiation (28, 29) . The weak PPARg partial agonistic activity of KY201 suggests that KY 201 more weakly promotes adipocyte differentiation and reduces osteoblast differentiation than rosiglitazone in mesenchymal stem cells. In rat BMSCs, rosiglitazone markedly increased GPDH activity, an adipocyte marker enzyme, and reduced ALP activity, an osteoblast marker enzyme; however, the effects of KY201 at higher concentrations were significantly weaker than those of rosiglitazone. The increasing effects of KY201 on the expression of PPARg2, C/EBPa, GPDH, lipoprotein lipase, adipocyte protein 2, and adiponectin, all bio marker genes of adipocytes (29, 32) , were also weaker than those of rosiglitazone in rat BMSCs cells. These findings demonstrate that KY201 partially activates PPARg, unlike rosiglitazone, a full PPARg agonist, resulting in fewer PPARgmediated adverse effects.
KY201 activates human, but not rodent PPARa (ref. 10 and unpublished data), leading to hypocholester olemic and body weight reducing effects in patients. PPARa agonists are known to have cholesterol and TGreducing effects, improve insulin sensitivity, and may also reduce body weight (33, 34) . KY201 increased hepatic AcyCoA activities in hamsters and reduced plasma cholesterol levels in hamsters, beagles, and monkeys (ref. 10 and unpublished data). The multifac eted characteristics of KY201, including weak PPARg and PPARa agonistic activities and PTP1B inhibitory activities, may beneficially exert additive and/or syner gistic effects in the treatment of type 2 diabetic patients at risk of cardiovascular disease, osteoporosis, and obesity. The therapeutic potentiality of KY201 could be further clarified in future studies using diabetic OVX rats or diabetic hamsters.
In conclusion, KY201, a partial PPARa/g agonist with PTP1B inhibitory activities, exhibits TG and NEFAreducing effects via insulin sensitization by the combination of PTP1B inhibitory activity and partial PPARg agonistic activity; and it has fewer PPARg mediated adverse effects such as reductions in BMD as well as fluid retention, cardiac hypertrophy, and increases in body and adipose weights due to partial PPARg activation. The combination of partial PPARg agonistic activities and PTP1B inhibitory activities is suggested to be a useful and effective approach in the treatment of type 2 diabetic patients at high risk of osteoporosis as well as cardiovascular disease and obesity.
